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Abstract
Background: Hyperuricaemia, the biochemical precursor to gout, has been shown to be an independent risk factor for
mortality from cardiovascular disease (CVD), although studies examining the clinical phenomenon of gout and risk of
CVD mortality report conflicting results. This study aimed to produce a pooled estimate of risk of mortality from
cardiovascular disease in patients with gout.
Design: Systematic review and meta-analysis.
Methods: Electronic bibliographic databases were searched from inception to November 2012, with results reviewed by
two independent reviewers. Studies were included if they reported data on CVD mortality in adults with gout who were
free of CVD at time of entry into the study. Pooled hazard ratios (HRs) for this association were calculated both
unadjusted and adjusted for traditional vascular risk factors.
Results: Six papers, including 223,448 patients, were eligible for inclusion (all (CVD) mortality n¼ 4, coronary heart
disease (CHD) mortality n¼ 3, and myocardial infarction mortality n¼ 3). Gout was associated with an excess risk of
CVD mortality (unadjusted HR 1.51 (95% confidence interval, CI, 1.17–1.84)) and CHD mortality (unadjusted HR 1.59,
95% CI 1.25–1.94)). After adjusting for traditional vascular risk factors, the pooled HR for both CVD mortality (HR 1.29,
95% CI 1.14–1.44) and CHD mortality (HR 1.42, 95% CI 1.22–1.63) remained statistically significant, but none of the
studies reported a significant association with myocardial infarction.
Conclusions: Gout increases the risk of mortality from CVD and CHD, but not myocardial infarction, independently of
vascular risk factors.
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Introduction
Gout is the most common form of inﬂammatory arth-
ritis and is estimated to aﬀect 1.4% of the population in
the UK and Germany and 4% in the USA.1,2 In recent
literature, both hyperuricaemia (the biochemical pre-
cursor to gout) and other inﬂammatory arthritides
have been shown to be independent risk factors for
mortality from cardiovascular disease (CVD).3–6
Several mechanisms for these associations have been
suggested, including immobility resulting from joint
pain and the additional cardiovascular risk conferred
by medications (such as nonsteroidal anti-inﬂammatory
drugs) used to manage these conditions.7 Latterly, it
has been suggested that systemic inﬂammation leads
to atherogenesis via endothelial dysfunction, decreased
arterial compliance, impaired blood ﬂow, and thus
a proatherogenic state.8 Therefore patients with
gout may be at increased vascular risk due to both
hyperuricaemia and crystal-induced inﬂammation,
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now recognized to persist even in the asymptomatic
intercritical period.9
However, the precise nature of the relationship
remains unclear since gout and CVD share many
common risk factors, such as hypertension and
obesity,10 introducing a potential source of
confounding.
Epidemiological studies examining the relationship
between gout and mortality from CVD have, to date,
reported conﬂicting ﬁndings even where they are under-
taken in similar populations and geographical
areas.11,12 Although one systematic review has been
published, no attempt was made to pool the data
described.13
For this reason, a systematic review and meta-ana-
lysis was undertaken to pool estimates of risk from
existing studies in order to examine the relationship
between gout and mortality from CVD.
Methods
Data sources and searches
Four electronic databases (MEDLINE, EMBASE,
CINAHL, and The Cochrane Library) were searched
from their inception until 17 November 2012, for stu-
dies of the association between gout and cardiovascular
mortality. Search terms describing gout (both free-text
and using database speciﬁc indexing trees) were com-
bined using the Boolean operator ‘AND’ with terms
describing the outcome of cardiovascular mortality. A
full list of search terms is available as an online supple-
ment. Reference lists of relevant reports and review art-
icles were screened to identify additional sources of
data.
Study selection
Studies were eligible for inclusion if they were of a trial
or epidemiological design (cohort, cross-sectional),
included adults aged 18 and over, and examined the
association of interest in a cohort of patients free
from vascular disease at diagnosis of gout. Case–
control studies were not included due to the likelihood
of sampling and recall bias associated with this design.
No geographical or language restrictions were imposed.
Two authors (LC, PC) independently screened all of
the titles and abstracts, after which, for those con-
sidered potentially relevant, full-text articles were
independently reviewed to determine eligibility for
inclusion. A third reviewer (SH) was identiﬁed in case
of disagreement or uncertainty. Studies reporting dif-
ferent deﬁnitions of cardiovascular mortality were
grouped according to these deﬁnitions for analysis.
All studies reported mortality coded according to the
International Classiﬁcation of Disease 9th or 10th revi-
sion, with comparisons suggesting both revisions iden-
tify a similar prevalence of medical conditions.14
Studies were included if they reported mortality from
any of: any CVD (ICD-9 codes 390–459, ICD-10 codes
I00–I99), coronary heart disease (CHD: including myo-
cardial infarction, MI; ICD-9 codes 410–414, ICD-10
codes I20–I25), or speciﬁcally MI (ICD-9 code 414,
ICD-10 codes I21–I22).
Data extraction and quality assessment
Data extraction and quality assessment was undertaken
by two reviewers independently (LC, PC), using a spe-
ciﬁcally designed data extraction form. Methodological
quality assessment criteria were based upon the
Newcastle–Ottawa scale.15 This consists of three com-
ponents; selection of study group, quality of adjustment
for confounding, and ascertainment of the outcome of
interest in the cohorts (maximum score of nine). Two
additional outcome criteria were added, assessing the
appropriateness of statistical methods and the separ-
ation of patients with gout from those with asymptom-
atic hyperuricaemia. Authors were contacted for
additional information where necessary. Higher meth-
odological quality is indicated by a higher score.
Data synthesis and analysis
Pooled estimates of hazard ratios (HRs) were calcu-
lated using the DerSimonian and Laird random-eﬀects
model,16 for mortality from any CVD or CHD. This
technique weights individual studies according to
sample size and variance, giving a pooled estimate
and 95% conﬁdence interval. A random eﬀects model
was chosen due to the number of papers included and
the likelihood of heterogeneity across study popula-
tions. I2 was used to calculate heterogeneity between
studies, estimating the percentage of variability in
results attributed to between-study diﬀerences.17
Statistical analysis was performed using STATA IC
12. Publication bias was assessed using funnel plots.
Begg’s rank correlation test and Egger’s linear regres-
sion test were used to detect any asymmetry in the
funnel plot that may be due to publication bias.18,19
Results
Description of the studies
The initial search identiﬁed 1293 potentially relevant
papers. After title and abstract screening, 1192 papers
were excluded either because they did not examine the
association of interest or were editorial or discursive
articles. The remaining 101 papers were reviewed in
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full text, and of these 95 were excluded (Figure 1). Six
studies reporting outcomes for 223,448 patients were
included: 149,532 men and 73,916 women. Four studies
reported on mortality from any CVD,11,12,20,21
three reported on mortality from CHD,11,12,20 and
three reported on mortality from MI.11,22,23 Two stu-
dies were conducted in Asia20,21 and four in the USA or
Canada.11,12,22,23 Numbers of participants ranged from
910512 to 57,852.23 Three studies included male-only
study populations.11,12,22 Follow up ranged from 56
months20 to 17 years.12 The characteristics of the
included studies are described in Table 1.
Scores for methodological quality of studies, where
the maximum score was 11, ranged from nine11,12
to 11,21 indicating a high level of methodological qual-
ity in all included studies.
Gout and mortality from any CVD
The pooled estimate of unadjusted HR for mortality
due to any CVD based on four studies was 1.51 (95%
CI 1.17–1.84) (comparing patients with gout to those
without gout).11,12,20,21 A signiﬁcant degree of study
heterogeneity was noted (I2¼ 66.8%, p¼ 0.029).
Based on the same four studies, after adjustment for
vascular risk factors, the pooled multivariate HR for
mortality due to any CVD was 1.29 (95% CI 1.13–
1.44), with no statistically signiﬁcant heterogeneity
(I2¼ 0%, p¼ 0.541) (Figure 2). The individual vascular
risk factors adjusted for in each study are shown in
Table 1. Examining the eﬀect of gender on overall
CVD mortality, two studies included only men,11,12
and whilst one study included both men and women,
so a separate analysis by gender was not undertaken.20
One study reported risk of CVD mortality by gender,
but did not ﬁnd increased risk in either gender (men:
HR 1.10, 95% CI 0.82–1.46; women: HR 1.51, 95% CI
1.00–2.30).21
Gout and mortality from CHD
The pooled estimate of unadjusted HR for mortality
due to CHD based on three studies was 1.59 (95% CI
1.25–1.94) (comparing patients with gout to those
Figure 1: 
1293 articles identified 
101 reviewed in full text 
6 papers included reporting on 
mortality from: 
Any cardiovascular disease (4) 
Coronary heart disease (3) 
Myocardial infarction (3) 
Excluded (95): 
No outcome of interest (51) 
Not trial (14) 
No gout group (9) 
No control groups (11) 
Inadequate methodological 
data (5) 
Not available in full text (5) 
Excluded based on 
title/abstract (1192) 
Figure 1. Selection of studies included in the review.
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without gout).11,12,21 Moderate heterogeneity was
noted (I2¼ 55%, p¼ 0.108). Based on the same three
studies, after adjustment for vascular risk factors, the
pooled multivariate HR for mortality due to CHD was
1.42 (95% CI 1.22–1.63), with no statistically signiﬁcant
heterogeneity (I2¼ 0%, p¼ 0.660) (Figure 3). Two of
these studies used a solely male population.11,12 In the
remaining study, an increased risk of mortality from
CHD was reported in women, HR 1.81, 95% CI
1.07–3.05), but not men, HR 1.16, 95% CI 0.81–1.67).21
Gout and mortality from MI
Three studies report on the association between gout
and mortality from MI. However, these studies were
unsuitable for meta-analysis due to signiﬁcant hetero-
geneity in the statistical analysis undertaken and out-
comes reported, and thus are described.
One study, from the USA, reported no increased risk
of fatal MI in 1123 men with gout compared to 11,743
age-matched male controls (odds ratio, OR, 0.96, 95%
CI 0.66–1.44).22 However, another paper reporting
results from this same study using a smaller population
of 655 men with gout compared to 8450 without did
report an excess risk of mortality from MI in gout
patients (HR 1.46, 95% CI 1.03–2.06).12 A further
study from Canada reported an excess risk of mortality
from MI in a mixed population of 9642 gout patients
compared to 48210 controls, but reported an increased
mortality risk only for women with gout (n¼ 3890)
(HR 1.57, 95% CI 1.18–2.09), but not men (HR 1.19,
95% CI 0.96–1.49).23 After adjustment for vascular risk
factors, none of the studies report a statistically signiﬁ-
cant excess risk of mortality from MI in gout patients
of either gender.
Publication bias assessment
No evidence of publication bias was seen for either any
CVD mortality (Begg’s tests: crude p¼ 0.149, multi-
variate p¼ 0.734; Egger’s tests: crude p¼ 0.06, multi-
variate p¼ 0.442) or CHD mortality (Begg’s tests:
crude p¼ 0.296, multivariate p¼ 0.296; Egger’s tests:
crude p¼ 0.164, multivariate p¼ 0.197).
Discussion
This systematic review and meta-analysis found a sig-
niﬁcant association between gout and mortality from
any CVD and CHD. It does not support an association
between gout and mortality from MI based upon cur-
rent evidence.
Our results are consistent with a previous systematic
review of four studies,13 which concluded that gout is
an independent risk factor for cardiovascular mortality.T
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.541)
Choi&Curhan
Krishnan
Teng
Kuo
studyid
1.29 (1.13, 1.44)
1.38 (1.15, 1.66)
1.21 (0.99, 1.49)
Hazard
1.23 (0.97, 1.56)
1.97 (1.08, 3.59)
Ratio (95% CI)
100.00
35.35
36.78
%
26.41
1.46
Weight
10 .5 1.5
Figure 2. Meta-analysis of adjusted findings of studies reporting mortality from any cardiovascular disease.
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.660)
Krishnan
studyid
Teng
Choi&Curhan
1.42 (1.22, 1.63)
1.35 (1.06, 1.72)
Ratio (95% CI)
1.35 (1.00, 1.82)
Hazard
1.55 (1.24, 1.93)
100.00
39.02
Weight
25.28
%
35.70
10 .5 1.5
Figure 3. Meta-analysis of adjusted findings of studies reporting mortality from coronary heart disease.
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Three of the studies included in that review were
included in this meta-analysis;11,12,20 however, one
was excluded24 as the study population consisted of
renal dialysis and transplantation patients, and was
not felt to be broadly representative of, or comparable
with, the wider gout population, and impaired renal
function is itself acknowledged to increase risk of car-
diovascular mortality.25,26 One more recent study was
included in our review.21 Our systematic review builds
on the previously published work by conducting the
ﬁrst meta-analysis determining the excess risk of car-
diovascular mortality associated with gout.
The precise relationship between gout and CVD
remains unclear. The persistence of excess risk of car-
diovascular and CHD mortality associated with gout in
the pooled multivariate analysis, even after adjustment
for traditional vascular risk factors, would suggest
there are other important factors which inﬂuence this
relationship. It is possible that this association is an
indirect one, and simply an extension of the increased
risk of CVD conferred by hyperuricaemia.3 This occurs
through a mechanism of ampliﬁed oxidation of
lipids and induction of cellular oxidative stress which
contributes to endothelial dysfunction, resulting in
decreased arterial compliance, impaired blood ﬂow,
and a proatherogenic state.27 However, since few stu-
dies include data on uric acid levels, we are unable to
explore this further. Studies have also demonstrated
renovascular disease, renal injury, and hypertension
can result from this hyperuricaemic-mediated endothe-
lial dysfunction,28 further contributing to cardiovascu-
lar risk. Uric acid is also thought to have direct
proinﬂammatory eﬀects on vascular cells,29,30 with evi-
dence that reduction of uric acid levels reduces cardio-
vascular risk.31 Allopurinol, the most commonly used
urate-lowering therapy, has been shown to improve
endothelial dysfunction,32,33 blood pressure,32,34
and exercise tolerance in patients with chronic stable
angina.35
However, given that other inﬂammatory arthritides,
such as rheumatoid arthritis and ankylosing spondyl-
itis, not associated with hyperuricaemia also confer
increased cardiovascular risk,4,5 it would seem likely
that the relationship is more complex. Common path-
ways of accelerated atherosclerosis resulting from endo-
thelial dysfunction and impaired arterial compliance, as
well as autoimmune inﬂammatory mechanisms invol-
ving proinﬂammatory cytokines such as tumour necro-
sis factor a and interleukins 1 and 6, by which
inﬂammatory arthritides increase cardiovascular risk,
have been suggested, and inﬂammatory activity is felt
to be the major risk factor for the development of sub-
sequent vascular disease.36 Monosodium urate crystals
deposited in gout have been shown to strongly induce
inﬂammation in humans, through direct neutrophil
activation and activation of the NALP3 inﬂammasome
resulting in the release of similar proinﬂammatory cyto-
kines, during an acute attack.28 There is growing evi-
dence that this inﬂammation persists between attacks,37
with recent ultrasound studies demonstrating the pres-
ence of inﬂammation and synovitis in the intercritical
period.9,38 This recent literature has conﬁrmed that
gout should be considered a chronic inﬂammatory
joint disease, and therefore, the possibility that persist-
ent inﬂammation is one mechanism for increased
burden of vascular disease in both gout and rheumatoid
arthritis. The eﬀect of inﬂammation on CVD has
prompted the European League Against Rheumatism
(EULAR) to publish recommendations for cardiovas-
cular screening and management in both rheumatoid
arthritis and gout patients,39,40 including an aggressive
approach to managing both risk factors and inﬂamma-
tory burden.
However, the reasons for the absence of a similar
association with mortality from MI remain unclear.
This diﬀerence may reﬂect the presence of alternative
underlying factors in the pathogenesis of MI when
compared with other forms of CHD. Evidence suggests
that coronary artery morphology is the most important
factor diﬀerentiating patients who experience angina,
compared to those with MI.41 It may also reﬂect mis-
classiﬁcation bias where, in the absence of post-mortem
examination, cause of death is recorded as CHD or
CVD rather than speciﬁcally MI. It may also result
from surveillance bias, whereby diagnosis of gout and
subsequent monitoring lead to increased likelihood of
detection and management of CHD, and better educa-
tion of patients about the need for prompt medical
attention at the onset of symptoms to prevent progres-
sion to MI. However, it may simply be that further
studies are required to investigate this particular
relationship.
The limitations of our review include the small
number of papers available for inclusion. However,
each of these studies uses a large study population
and, combined, the number of patients included in
this meta-analysis exceeds 220,000. Moreover, by
undertaking the meta-analysis in a stepwise fashion,
pooling the studies one-by-one in chronological order,
the pooled HR was not signiﬁcantly altered from the
HR reported in the ﬁrst paper (published in 2007) after
the addition of any of the later papers.
Despite a comprehensive search strategy, the possi-
bility remains that some relevant articles may not have
been identiﬁed. Similarly, papers with negative ﬁndings
are less likely to be published, although there was no
signiﬁcant indication of publication bias from Begg’s
and Egger’s tests. However, it must be acknowledged
that Begg’s and Egger’s tests have low power to detect
biases where study numbers are small.42
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There was some heterogeneity between papers in the
deﬁnitions of gout cases and the vascular risk factors
included in the multivariate analyses, and unmeasured
confounding must be considered given the observa-
tional nature of the included studies. Misclassiﬁcation
bias may also occur where studies relied upon diagnos-
tic codes or death certiﬁcates to deﬁne outcomes.
The strengths of our review are that only large
cohort studies are included, with participants being
free of CVD at baseline. Data extraction and thorough
methodological quality assessment was undertaken by
two reviewers independently. Crude and multivariate
data were pooled separately and potential sources of
heterogeneity examined. Finally, no evidence of publi-
cation bias was found in our review.
In conclusion, whilst observational studies cannot
demonstrate causation, this meta-analysis of large,
high-quality cohort studies strongly supports gout as
an independent risk factor for mortality from CVD
and CHD. Current evidence does not support such an
association with MI. The clinical implications of this
review are the need to promote identiﬁcation and man-
agement of cardiovascular risk factors in patients with
gout, but also to identify and optimally manage gout in
patients at risk of CVD. Further research will be
required to establish whether the optimal management
of gout, or the aggressive management of cardiovascu-
lar risk factors reduces negative outcomes for these
patients.
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